Drug target · DRD3
D3
Dopamine D3 receptor
5 compounds in the CNS pipeline act on D3.
Compounds targeting D3
| Compound | Action | Affinity | Lead program | Developer |
|---|---|---|---|---|
| ABBV-932primarySmall molecule | Partial agonist | — | Phase 2Bipolar depression | Gedeon Richter Plc. |
| ALTO-207primarySmall molecule | Agonist | pKi 8.5 | Phase 2Treatment-resistant depression | Alto Neuroscience, Inc. |
| Brilaroxazine (RP5063)Small molecule | Partial agonist | Ki 3.7 nM | Phase 3Schizophrenia | Reviva Pharmaceuticals Holdings, Inc. |
| LB-102 (N-methylamisulpride)Small molecule | Antagonist | Ki 0.8 nM | Phase 3Schizophrenia | LB Pharmaceuticals Inc. |
| ENX-104Small molecule | Antagonist | — | Phase 1Major depressive disorder | Engrail Therapeutics, Inc. |